CILIARY NEUROTROPHIC FACTOR THERAPY FOR MACULAR TELANGIECTASIA TYPE 2: A Systematic Review.

RetinaSep 1, 2026
Clinical ResearchOphthalmology

Aswen Sriranganathan, Zwetlana Rajesh, Andrew Mihalache et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of ciliary neurotrophic factor therapy on structural and functional outcomes in patients with Type 2 macular telangiectasia (MacTel). Analyzing five studies involving 498 eyes from 422 patients, the review found that treatment may slow retinal degeneration and preserve visual function, with one randomized trial showing reduced decline in reading speed in treated eyes compared to sham.

Key findings

  • One randomized trial showed decreased progression of retinal degeneration in treated eyes compared to sham.
  • Ciliary neurotrophic factor therapy demonstrated good tolerance with no significant differences in visual acuity over 36 months.
  • Smaller changes in ellipsoid zone defect areas were observed in treated eyes compared to sham-treated eyes.

Why it matters

Understanding the potential benefits of ciliary neurotrophic factor therapy is crucial for managing patients with MacTel, as it may offer a means to slow disease progression and maintain visual function.

Source

PubMed · PMID 41954482

Published in Retina. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.